Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00608829 · ClinicalTrials.gov registry record · Phase 2

GORE TAG® Thoracic Endoprosthesis - 45 mm for the Treatment of Aneurysms of the Descending Thoracic Aorta

A Phase 2 study of Aortic Aneurysm, Thoracic, sponsored by W.L.Gore & Associates.

Completed
Registry status
Phase 2
Development phase
23
Enrollment target
1
Study location

NCT00608829 is a Phase 2 study of Aortic Aneurysm, Thoracic that has completed, run by W.L.Gore & Associates. The registered enrollment target is 23 participants, below the 240-participant average among 4 other Aortic Aneurysm, Thoracic trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00608829, a Phase 2 study of Aortic Aneurysm, Thoracic, has completed, sponsored by W.L.Gore & Associates.

COMPLETED
Registry status
Phase 2
Development phase
23 participants
Enrollment target
1
Study location

Study Summary

The objective of this study is to assess the safety and efficacy of the 45 mm TAG device in subjects with aneurysms of the descending thoracic aorta.

Conditions Studied

Interventions

  • DEVICE GORE TAG® Thoracic Endoprosthesis

Study Locations (1)

Pennsylvania

  • University of Pittsburgh Medical Center - Pittsburgh

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2007-02
Est. Completion 2014-09
Phase Phase 2

Sponsor

W.L.Gore & Associates

53 total trials

What the Registry Record Tells You About NCT00608829

The ClinicalTrials.gov registry entry for NCT00608829 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 240-participant average among 4 other Aortic Aneurysm, Thoracic trials with a reported enrollment target (90% lower). The listed sponsor is W.L.Gore & Associates, which has 53 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Aortic Aneurysm, Thoracic appearing as the primary indexed condition, and to 1 intervention - of which GORE TAG® Thoracic Endoprosthesis is the first listed.

NCT00608829 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00608829 about?

NCT00608829 is a clinical study titled "GORE TAG® Thoracic Endoprosthesis - 45 mm for the Treatment of Aneurysms of the Descending Thoracic Aorta". The objective of this study is to assess the safety and efficacy of the 45 mm TAG device in subjects with aneurysms of the descending thoracic aorta.

What is the current status of trial NCT00608829?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2007-02. Estimated completion is 2014-09.

What conditions does trial NCT00608829 study?

This clinical trial studies the following conditions: Aortic Aneurysm, Thoracic.

What interventions are being tested in trial NCT00608829?

The interventions under investigation include: GORE TAG® Thoracic Endoprosthesis (DEVICE).

Who is sponsoring clinical trial NCT00608829?

This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00608829 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aortic Aneurysm, Thoracic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.